查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1790236

北美临床试验市场规模、份额和趋势分析报告：按阶段、研究设计、适应症、服务、赞助商、国家和细分市场预测，2025 年至 2033 年

North America Clinical Trials Market Size, Share & Trends Analysis Report By Phase, By Study Design, By Indication, By Indication by Study Design, By Service, By Sponsor, By Country, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

北美临床检测市场概览

北美临床测试市场在 2024 年的价值估计为 430.3 亿美元，预计到 2033 年将达到 773.2 亿美元，2025 年至 2033 年的复合年增长率为 6.98%。市场成长受到学术研究机构强大生态系统、製药公司不断增加的研发资金以及支持大量早期至后期测试的专业委外研发机构(CRO) 的推动。

北美临床检测市场由高度发展的研究基础设施以及众多始终将临床开发放在首位的全球製药、生物技术和医疗设备公司所驱动。梅奥诊所、MD 安德森癌症中心和哈佛医学院等众多学术研究中心和医院的存在，促进了早期测试领域的创新和伙伴关係。此外，美国食品药物管理局 (FDA) 等监管机构为临床实验申请 (IND)、孤儿药认定和自适应测试设计提供了完善的框架，从而降低了进入门槛并加快了临床开发进度。

此外，产业相关人员、数位健康创新者和患者权益团体之间的合作正在加强。製药公司不仅在扩展自己的研发开发平臺，还积极与合约研究组织 (CRO) 合作，以简化试验设计、场地管理和监管提交流程。这一趋势使申办方能够在不损害资料完整性或病患安全的情况下加快进度。同样，在倡导基金会和公共卫生宣传活动的支持下，患者意识和教育的提高正在导致更多的临床试验参与，特别是在肿瘤学和罕见疾病等复杂领域。在联邦指导方针和多元化授权的支持下，朝着更具包容性的招募策略转变，正在确保临床结果更好地反映现实世界的人群。

目录

第一章调查方法与范围

第二章执行摘要

3. 北美临床测试市场变数、趋势和范围

  • 市场体系展望
    • 母市场展望
    • 辅助市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
    • 市场机会分析
    • 市场问题分析
  • 研发成本分析
    • 主要赞助商研发投资分析（2021-2024）
    • 创业投资与政府资金筹措场景
  • 临床试验设计与分析
  • 产业生态系统分析
  • 科技
  • 定价分析
  • 2024年临床检测量分析
    • 各地区临床试验总数（2024年）
    • 临床试验总数（分阶段）（2024年）
    • 依研究设计分類的临床试验总数（2024 年）
    • 依主要适应症分類的临床试验总数（2024年）
  • 临床测试市场分析工具
    • 波特五力分析
    • PESTEL 与 SWOT 分析

第四章北美临床测试市场：阶段、估计和趋势分析

  • 细分仪表板
  • 北美临床测试市场：相位波动分析
  • 阶段，2021-2033
  • 第一阶段
  • 第二阶段
  • 第三阶段
  • 第四阶段

第五章北美临床测试市场：按研究设计的估计和趋势分析

  • 细分仪表板
  • 北美临床测试市场：研究设计变异分析
  • 依研究设计，2021-2033 年
  • 侵入性
  • 观察
  • 扩展访问

第六章北美临床测试市场：按适应症的估计和趋势分析

  • 细分仪表板
  • 北美临床检测市场：适应症差异分析
  • 依适应症，2021-2033年
  • 自体免疫/炎症
    • 类风湿性关节炎
    • 多发性硬化症
    • 骨关节炎
    • 大肠激躁症（IBS）
    • 其他的
  • 疼痛管理
    • 慢性疼痛
    • 急性疼痛
  • 肿瘤学
    • 血癌
    • 固态肿瘤
    • 其他的
  • 中枢神经系统症状
    • 癫痫
    • 帕金森氏症（PD）
    • 亨丁顿舞蹈症
    • 中风
    • 创伤性脑损伤（TBI）
    • 肌萎缩侧索硬化症（ALS）
    • 肌肉再生
    • 其他的
  • 糖尿病
  • 肥胖
  • 心血管疾病
  • 其他的

第七章北美临床测试市场：适应症、趋势与研究设计分析

  • 细分仪表板
  • 北美临床测试市场：研究设计变异分析
  • 依研究设计，依研究设计，2021-2033
  • 自体免疫/炎症
    • 干预测试
    • 观察测试
    • 扩展访问检查
  • 疼痛管理
    • 干预测试
    • 观察测试
    • 扩展访问检查
  • 肿瘤学
    • 干预测试
    • 观察测试
    • 扩展访问检查
  • 中枢神经系统症状
    • 干预测试
    • 观察测试
    • 扩展访问检查
  • 糖尿病
    • 干预测试
    • 观察测试
    • 扩展访问检查
  • 肥胖
    • 干预测试
    • 观察测试
    • 扩展访问检查
  • 心血管疾病
    • 干预测试
    • 观察测试
    • 扩展访问检查
  • 其他的
    • 干预测试
    • 观察测试
    • 扩展访问检查

第 8 章：北美临床测试市场：按服务进行的估计和趋势分析

  • 细分仪表板
  • 北美临床检测市场：服务差异分析
  • 按服务划分，2021-2033 年
  • 通讯协定设计
  • 区域识别
  • 病患招募
  • 化验服务
  • 分析测试服务
  • 临床实验室数据管理服务
  • 其他的

第九章北美临床测试市场：赞助商的估计和趋势分析

  • 细分仪表板
  • 北美临床测试市场：赞助商变更分析
  • 按赞助商，2021-2033 年
  • 製药和生物製药公司
  • 医疗设备公司
  • 其他的

第 10 章北美临床测试市场：各国概况、估算与趋势分析

  • 国家展望
  • 北美临床检测市场：国家差异分析
  • 按国家/地区，2021-2033 年
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥

第十一章竞争格局

  • 公司分类
    • 创新者
    • 市场领导者
    • 新参与企业
  • 2024年企业市场估值分析
  • 主要企业简介
    • Pfizer Inc.
    • Merck & Co., Inc.
    • AbbVie Inc.
    • Amgen Inc.
    • Bristol Myers Squibb
    • Gilead Sciences, Inc.
    • Eli Lilly and Company
    • Biogen Inc.
    • Moderna, Inc.
    • Labcorp
    • IQVIA, Inc.
    • Syneos Health
    • PAREXEL International Corporation
    • ICON Plc
    • Thermo Fisher Scientific Inc.
    • Charles River Laboratories International Inc.
    • Medpace Holdings, Inc.
    • Worldwide Clinical Trials
    • Clinipace Inc.
    • Fortrea
  • 其他主要市场参与企业名单
Product Code: GVR-4-68040-202-2

North America Clinical Trials Market Summary

The North America clinical trials market size was estimated at USD 43.03 billion in 2024 and is projected to reach USD 77.32 billion by 2033, growing at a CAGR of 6.98% from 2025 to 2033. The market growth is driven by a robust ecosystem of academic research institutions, growing research and development funding by pharmaceutical companies, and specialized contract research organizations (CROs) that support a high volume of early-to late-phase studies.

The North America clinical trials market is propelled by a highly developed research infrastructure and a concentration of global pharmaceutical, biotechnology, and medical device companies that consistently prioritize clinical development. The presence of several academic research centers and hospitals such as the Mayo Clinic, MD Anderson Cancer Center, and Harvard Medical School is driving the innovation and partnerships in early-stage trials. Moreover, the regulatory agencies such as the U.S. FDA are offering well-established frameworks for Investigational New Drug (IND) applications, Orphan Drug Designations, and adaptive trial designs which is lowering the entry barriers and accelerating the clinical timeline.

Furthermore, increasing collaboration between industry stakeholders, digital health innovators, and patient advocacy groups. Pharmaceutical companies are not only expanding their in-house R&D pipelines but are also actively partnering with CROs to streamline study design, site management, and regulatory submissions. This trend allows sponsors to accelerate timelines without compromising on data integrity or patient safety. Similarly, rising patient awareness and education, often supported by advocacy foundations and public health campaigns has resulted in greater trial participation, particularly in complex areas such as oncology and rare diseases. The shift toward more inclusive enrollment strategies, supported by federal guidelines and diversity mandates, ensures that clinical outcomes better reflect real-world populations.

North America Clinical Trials Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the North America clinical trials market report based on phase, study design, indication, indication by study design, service, sponsor, and country:

  • Phase Outlook (Revenue, USD Million, 2021 - 2033)
  • Phase I
  • Phase II
  • Phase III
  • Phase IV
  • Study Design Outlook (Revenue, USD Million, 2021 - 2033)
  • Interventional Trials
  • Observational Trials
  • Expanded Access Trials
  • Indication Outlook (Revenue, USD Million, 2021 - 2033)
  • Autoimmune/Inflammation
    • Rheumatoid Arthritis
    • Multiple Sclerosis
    • Osteoarthritis
    • Irritable Bowel Syndrome (IBS)
    • Others
  • Pain Management
    • Chronic Pain
    • Acute Pain
  • Oncology
    • Blood Cancer
    • Solid Tumors
    • Others
  • CNS Conditions
    • Epilepsy
    • Parkinson's Disease (PD)
    • Huntington's Disease
    • Stroke
    • Traumatic Brain Injury (TBI)
    • Amyotrophic Lateral Sclerosis (ALS)
    • Muscle Regeneration
    • Others
  • Diabetes
  • Obesity
  • Cardiovascular Diseases
  • Others
  • Indication by Study Design Outlook (Revenue, USD Million, 2021 - 2033)
  • Autoimmune/Inflammation
    • Interventional Trials
    • Observational Trials
    • Expanded Access Trials
  • Pain Management
    • Interventional Trials
    • Observational Trials
    • Expanded Access Trials
  • Oncology
    • Interventional Trials
    • Observational Trials
    • Expanded Access Trials
  • CNS Conditions
    • Interventional Trials
    • Observational Trials
    • Expanded Access Trials
  • Diabetes
    • Interventional Trials
    • Observational Trials
    • Expanded Access Trials
  • Obesity
    • Interventional Trials
    • Observational Trials
    • Expanded Access Trials
  • Cardiovascular Diseases
    • Interventional Trials
    • Observational Trials
    • Expanded Access Trials
  • Others
    • Interventional Trials
    • Observational Trials
    • Expanded Access Trials
  • Service Outlook (Revenue, USD Million, 2021 - 2033)
  • Protocol Designing
  • Site Identification
  • Patient Recruitment
  • Laboratory Services
  • Analytical Testing Services
  • Clinical Trial Data Management Services
  • Others
  • Sponsor Outlook (Revenue, USD Million, 2021 - 2033)
  • Pharmaceutical & Biopharmaceutical Companies
  • Medical Device Companies
  • Others
  • Country Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Value chain based analysis (Model 2)
    • 1.7.3. Multivariate Analysis (Model 3)
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. North America Clinical Trials Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
    • 3.2.3. Market Opportunity Analysis
    • 3.2.4. Market Challenge Analysis
  • 3.3. R&D Spending Analysis
    • 3.3.1. R&D Investment Analysis, by Key Sponsors (2021-2024)
    • 3.3.2. Venture Capital & Government Funding Scenario
  • 3.4. Clinical Trials Design Analysis
  • 3.5. Industry Ecosystem Analysis
  • 3.6. Technology Landscape
  • 3.7. Pricing Analysis
  • 3.8. Clinical Trial Volume Analysis, 2024
    • 3.8.1. Total Number of Clinical Trials, By Region (2024)
    • 3.8.2. Total Number of Clinical Trials, By Phase (2024)
    • 3.8.3. Total Number of Clinical Trials, By Study Design (2024)
    • 3.8.4. Total Number of Clinical Trials, By Key Indication (2024)
  • 3.9. Clinical Trials Market Analysis Tools
    • 3.9.1. Porter's Five Forces Analysis
    • 3.9.2. PESTEL by SWOT Analysis

Chapter 4. North America Clinical Trials Market: Phase Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. North America Clinical Trials Market: Phase Movement Analysis
  • 4.3. North America Clinical Trials Market Estimates and Forecasts, by Phase, 2021 - 2033 (USD Million)
  • 4.4. Phase I
    • 4.4.1. Phase I Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Phase II
    • 4.5.1. Phase II Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Phase III
    • 4.6.1. Phase III Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.7. Phase IV
    • 4.7.1. Phase IV Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. North America Clinical Trials Market: Study Design Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. North America Clinical Trials Market: Study Design Movement Analysis
  • 5.3. North America Clinical Trials Market Estimates and Forecasts, by Study Design, 2021 - 2033 (USD Million)
  • 5.4. Interventional
    • 5.4.1. Interventional Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Observational
    • 5.5.1. Observational Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Expanded Access
    • 5.6.1. Expanded Access Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. North America Clinical Trials Market: Indication Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. North America Clinical Trials Market: Indication Movement Analysis
  • 6.3. North America Clinical Trials Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • 6.4. Autoimmune/Inflammation
    • 6.4.1. Autoimmune/Inflammation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.2. Rheumatoid Arthritis
      • 6.4.2.1. Rheumatoid Arthritis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.3. Multiple Sclerosis
      • 6.4.3.1. Multiple Sclerosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.4. Osteoarthritis
      • 6.4.4.1. Osteoarthritis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.5. Irritable Bowel Syndrome (IBS)
      • 6.4.5.1. Irritable Bowel Syndrome (IBS) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.6. Others
      • 6.4.6.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Pain Management
    • 6.5.1. Pain Management Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.2. Chronic Pain
      • 6.5.2.1. Chronic Pain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.3. Acute Pain
      • 6.5.3.1. Acute Pain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Oncology
    • 6.6.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.2. Blood Cancer
      • 6.6.2.1. Blood Cancer Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.3. Solid Tumors
      • 6.6.3.1. Solid Tumors Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.4. Others
      • 6.6.4.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. CNS Conditions
    • 6.7.1. CNS Conditions Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.2. Epilepsy
      • 6.7.2.1. Epilepsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.3. Parkinson's Disease (PD)
      • 6.7.3.1. Parkinson's Disease (PD) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.4. Huntington's Disease
      • 6.7.4.1. Huntington's Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.5. Stroke
      • 6.7.5.1. Stroke Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.6. Traumatic Brain Injury (TBI)
      • 6.7.6.1. Traumatic Brain Injury (TBI) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.7. Amyotrophic Lateral Sclerosis (ALS)
      • 6.7.7.1. Amyotrophic Lateral Sclerosis (ALS) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.8. Muscle Regeneration
      • 6.7.8.1. Muscle Regeneration Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.9. Others
      • 6.7.9.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Diabetes
    • 6.8.1. Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.9. Obesity
    • 6.9.1. Obesity Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.10. Cardiovascular Diseases
    • 6.10.1. Cardiovascular Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.11. Others
    • 6.11.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. North America Clinical Trials Market: Indication by Study Design Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. North America Clinical Trials Market: Indication by Study Design Movement Analysis
  • 7.3. North America Clinical Trials Market Estimates and Forecasts, by Indication by Study Design, 2021 - 2033 (USD Million)
  • 7.4. Autoimmune/Inflammation
    • 7.4.1. Autoimmune/Inflammation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.2. Interventional Trials
      • 7.4.2.1. Interventional Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.3. Observational Trials
      • 7.4.3.1. Observational Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.4. Expanded Access Trials
      • 7.4.4.1. Expanded Access Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Pain Management
    • 7.5.1. Pain Management Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.2. Interventional Trials
      • 7.5.2.1. Interventional Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.3. Observational Trials
      • 7.5.3.1. Observational Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.4. Expanded Access Trials
      • 7.5.4.1. Expanded Access Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Oncology
    • 7.6.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.2. Interventional Trials
      • 7.6.2.1. Interventional Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.3. Observational Trials
      • 7.6.3.1. Observational Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.4. Expanded Access Trials
      • 7.6.4.1. Expanded Access Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7. CNS Conditions
    • 7.7.1. CNS Conditions Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.2. Interventional Trials
      • 7.7.2.1. Interventional Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.3. Observational Trials
      • 7.7.3.1. Observational Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.4. Expanded Access Trials
      • 7.7.4.1. Expanded Access Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8. Diabetes
    • 7.8.1. Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.2. Interventional Trials
      • 7.8.2.1. Interventional Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.3. Observational Trials
      • 7.8.3.1. Observational Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.4. Expanded Access Trials
      • 7.8.4.1. Expanded Access Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.9. Obesity
    • 7.9.1. Obesity Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.9.2. Interventional Trials
      • 7.9.2.1. Interventional Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.9.3. Observational Trials
      • 7.9.3.1. Observational Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.9.4. Expanded Access Trials
      • 7.9.4.1. Expanded Access Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.10. Cardiovascular Diseases
    • 7.10.1. Cardiovascular Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.10.2. Interventional Trials
      • 7.10.2.1. Interventional Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.10.3. Observational Trials
      • 7.10.3.1. Observational Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.10.4. Expanded Access Trials
      • 7.10.4.1. Expanded Access Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.11. Others
    • 7.11.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.11.2. Interventional Trials
      • 7.11.2.1. Interventional Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.11.3. Observational Trials
      • 7.11.3.1. Observational Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.11.4. Expanded Access Trials
      • 7.11.4.1. Expanded Access Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. North America Clinical Trials Market: Service Estimates & Trend Analysis

  • 8.1. Segment Dashboard
  • 8.2. North America Clinical Trials Market: Service Movement Analysis
  • 8.3. North America Clinical Trials Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • 8.4. Protocol Designing
    • 8.4.1. Protocol Designing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5. Site Identification
    • 8.5.1. Site Identification Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6. Patient Recruitment
    • 8.6.1. Patient Recruitment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7. Laboratory Services
    • 8.7.1. Laboratory Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8. Analytical Testing Services
    • 8.8.1. Analytical Testing Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.9. Clinical Trial Data Management Services
    • 8.9.1. Clinical Trial Data Management Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.10. Others
    • 8.10.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. North America Clinical Trials Market: Sponsor Estimates & Trend Analysis

  • 9.1. Segment Dashboard
  • 9.2. North America Clinical Trials Market: Sponsor Movement Analysis
  • 9.3. North America Clinical Trials Market Estimates and Forecasts, by Sponsor, 2021 - 2033 (USD Million)
  • 9.4. Pharmaceutical & Biopharmaceutical Companies
    • 9.4.1. Pharmaceutical & Biopharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5. Medical Device Companies
    • 9.5.1. Medical Device Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.6. Others
    • 9.6.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 10. North America Clinical Trials Market: Country Estimates & Trend Analysis

  • 10.1. Country Outlook
  • 10.2. North America Clinical Trials Market: Country Movement Analysis
  • 10.3. North America Clinical Trials Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • 10.4. North America
    • 10.4.1. North America Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 10.4.2. U.S.
      • 10.4.2.1. Key Country Dynamics
      • 10.4.2.2. Competitive Scenario
      • 10.4.2.3. Regulatory Framework
      • 10.4.2.4. U.S. Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 10.4.3. Canada
      • 10.4.3.1. Key Country Dynamics
      • 10.4.3.2. Competitive Scenario
      • 10.4.3.3. Regulatory Framework
      • 10.4.3.4. Canada Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 10.4.4. Mexico
      • 10.4.4.1. Key Country Dynamics
      • 10.4.4.2. Competitive Scenario
      • 10.4.4.3. Regulatory Framework
      • 10.4.4.4. Mexico Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 11. Competitive Landscape

  • 11.1. Company Categorization
    • 11.1.1. Innovators
    • 11.1.2. Market Leaders
    • 11.1.3. Emerging Players
  • 11.2. Company Market Assessment Analysis, 2024
  • 11.3. Key Company Profiles
    • 11.3.1. Pfizer Inc.
      • 11.3.1.1. Company Overview
      • 11.3.1.2. Financial Performance
      • 11.3.1.3. Service Benchmarking
      • 11.3.1.4. Strategic Initiatives
    • 11.3.2. Merck & Co., Inc.
      • 11.3.2.1. Company Overview
      • 11.3.2.2. Financial Performance
      • 11.3.2.3. Service Benchmarking
      • 11.3.2.4. Strategic Initiatives
    • 11.3.3. AbbVie Inc.
      • 11.3.3.1. Company Overview
      • 11.3.3.2. Financial Performance
      • 11.3.3.3. Service Benchmarking
      • 11.3.3.4. Strategic Initiatives
    • 11.3.4. Amgen Inc.
      • 11.3.4.1. Company Overview
      • 11.3.4.2. Financial Performance
      • 11.3.4.3. Service Benchmarking
      • 11.3.4.4. Strategic Initiatives
    • 11.3.5. Bristol Myers Squibb
      • 11.3.5.1. Company Overview
      • 11.3.5.2. Financial Performance
      • 11.3.5.3. Service Benchmarking
      • 11.3.5.4. Strategic Initiatives
    • 11.3.6. Gilead Sciences, Inc.
      • 11.3.6.1. Company Overview
      • 11.3.6.2. Financial Performance
      • 11.3.6.3. Service Benchmarking
      • 11.3.6.4. Strategic Initiatives
    • 11.3.7. Eli Lilly and Company
      • 11.3.7.1. Company Overview
      • 11.3.7.2. Financial Performance
      • 11.3.7.3. Service Benchmarking
      • 11.3.7.4. Strategic Initiatives
    • 11.3.8. Biogen Inc.
      • 11.3.8.1. Company Overview
      • 11.3.8.2. Financial Performance
      • 11.3.8.3. Service Benchmarking
      • 11.3.8.4. Strategic Initiatives
    • 11.3.9. Moderna, Inc.
      • 11.3.9.1. Company Overview
      • 11.3.9.2. Financial Performance
      • 11.3.9.3. Service Benchmarking
      • 11.3.9.4. Strategic Initiatives
    • 11.3.10. Labcorp
      • 11.3.10.1. Company Overview
      • 11.3.10.2. Financial Performance
      • 11.3.10.3. Service Benchmarking
      • 11.3.10.4. Strategic Initiatives
    • 11.3.11. IQVIA, Inc.
      • 11.3.11.1. Company Overview
      • 11.3.11.2. Financial Performance
      • 11.3.11.3. Service Benchmarking
      • 11.3.11.4. Strategic Initiatives
    • 11.3.12. Syneos Health
      • 11.3.12.1. Company Overview
      • 11.3.12.2. Financial Performance
      • 11.3.12.3. Service Benchmarking
      • 11.3.12.4. Strategic Initiatives
    • 11.3.13. PAREXEL International Corporation
      • 11.3.13.1. Company Overview
      • 11.3.13.2. Financial Performance
      • 11.3.13.3. Service Benchmarking
      • 11.3.13.4. Strategic Initiatives
    • 11.3.14. ICON Plc
      • 11.3.14.1. Company Overview
      • 11.3.14.2. Financial Performance
      • 11.3.14.3. Service Benchmarking
      • 11.3.14.4. Strategic Initiatives
    • 11.3.15. Thermo Fisher Scientific Inc.
      • 11.3.15.1. Company Overview
      • 11.3.15.2. Financial Performance
      • 11.3.15.3. Service Benchmarking
      • 11.3.15.4. Strategic Initiatives
    • 11.3.16. Charles River Laboratories International Inc.
      • 11.3.16.1. Company Overview
      • 11.3.16.2. Financial Performance
      • 11.3.16.3. Service Benchmarking
      • 11.3.16.4. Strategic Initiatives
    • 11.3.17. Medpace Holdings, Inc.
      • 11.3.17.1. Company Overview
      • 11.3.17.2. Financial Performance
      • 11.3.17.3. Service Benchmarking
      • 11.3.17.4. Strategic Initiatives
    • 11.3.18. Worldwide Clinical Trials
      • 11.3.18.1. Company Overview
      • 11.3.18.2. Financial Performance
      • 11.3.18.3. Service Benchmarking
      • 11.3.18.4. Strategic Initiatives
    • 11.3.19. Clinipace Inc.
      • 11.3.19.1. Company Overview
      • 11.3.19.2. Financial Performance
      • 11.3.19.3. Service Benchmarking
      • 11.3.19.4. Strategic Initiatives
    • 11.3.20. Fortrea
      • 11.3.20.1. Company Overview
      • 11.3.20.2. Financial Performance
      • 11.3.20.3. Service Benchmarking
      • 11.3.20.4. Strategic Initiatives
  • 11.4. List of Other Key Market Players

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 North America Clinical Trials Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • Table 4 North America Clinical Trials Market Estimates and Forecasts, by Phase, 2021 - 2033 (USD Million)
  • Table 5 North America Clinical Trials Market Estimates and Forecasts, by Study Design, 2021 - 2033 (USD Million)
  • Table 6 North America Clinical Trials Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 7 North America Clinical Trials Market Estimates and Forecasts, Indication by Study Design, 2021 - 2033 (USD Million)
  • Table 8 North America Clinical Trials Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 9 North America Clinical Trials Market Estimates and Forecasts, by Sponsor, 2021 - 2033 (USD Million)
  • Table 10 U.S. Clinical Trials Market Estimates and Forecasts, by Phase, 2021 - 2033 (USD Million)
  • Table 11 U.S. Clinical Trials Market Estimates and Forecasts, by Study Design, 2021 - 2033 (USD Million)
  • Table 12 U.S. Clinical Trials Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 13 U.S. Clinical Trials Market Estimates and Forecasts, Indication by Study Design, 2021 - 2033 (USD Million)
  • Table 14 U.S. Clinical Trials Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 15 U.S. Clinical Trials Market Estimates and Forecasts, by Sponsor, 2021 - 2033 (USD Million)
  • Table 16 Canada Clinical Trials Market Estimates and Forecasts, by Phase, 2021 - 2033 (USD Million)
  • Table 17 Canada Clinical Trials Market Estimates and Forecasts, by Study Design, 2021 - 2033 (USD Million)
  • Table 18 Canada Clinical Trials Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 19 Canada Clinical Trials Market Estimates and Forecasts, Indication by Study Design, 2021 - 2033 (USD Million)
  • Table 20 Canada Clinical Trials Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 21 Canada Clinical Trials Market Estimates and Forecasts, by Sponsor, 2021 - 2033 (USD Million)
  • Table 22 Mexico Clinical Trials Market Estimates and Forecasts, by Phase, 2021 - 2033 (USD Million)
  • Table 23 Mexico Clinical Trials Market Estimates and Forecasts, by Study Design, 2021 - 2033 (USD Million)
  • Table 24 Mexico Clinical Trials Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 25 Mexico Clinical Trials Market Estimates and Forecasts, Indication by Study Design, 2021 - 2033 (USD Million)
  • Table 26 Mexico Clinical Trials Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 27 Mexico Clinical Trials Market Estimates and Forecasts, by Sponsor, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Clinical Trials Market Segmentation
  • Fig. 2 Market Research Process
  • Fig. 3 Information Procurement
  • Fig. 4 Primary Research Pattern
  • Fig. 5 Market Research Approaches
  • Fig. 6 Value Chain-Based Sizing & Forecasting
  • Fig. 7 Market Formulation & Validation
  • Fig. 8 Market Dynamics
  • Fig. 9 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 10 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 11 Porter's Five Forces Analysis
  • Fig. 12 PESTEL by SWOT Analysis
  • Fig. 13 North America Phase I Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 14 North America Phase II Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 15 North America Phase III Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 16 North America Phase IV Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 17 North America Interventional Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 18 North America Observational Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 19 North America Expanded Access Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 20 North America Autoimmune/Inflammation Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 21 North America Rheumatoid Arthritis Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 22 North America Multiple Sclerosis Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 23 North America Osteoarthritis Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 24 North America Irritable Bowel Syndrome (IBS) Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 25 North America Others Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 26 North America Pain Management Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 27 North America Chronic Pain Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 28 North America Acute Pain Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 29 North America Oncology Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 30 North America Blood Cancer Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 31 North America Solid Tumors Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 32 North America Others Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 33 North America CNS Conditions Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 34 North America Epilepsy Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 35 North America Parkinson's Disease (PD) Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 36 North America Huntington's Disease Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 37 North America Stroke Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 38 North America Traumatic Brain Injury (TBI) Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 39 North America Amyotrophic Lateral Sclerosis (ALS) Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 40 North America Muscle Regeneration Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 41 North America Others Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 42 North America Diabetes Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 43 North America Obesity Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 44 North America Cardiovascular Diseases Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 45 North America Others Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 46 North America Autoimmune/Inflammation Interventional Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 47 North America Autoimmune/Inflammation Observational Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 48 North America Autoimmune/Inflammation Expanded Access Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 49 North America Pain Management Interventional Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 50 North America Pain Management Observational Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 51 North America Pain Management Expanded Access Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 52 North America Oncology Interventional Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 53 North America Oncology Observational Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 54 North America Oncology Expanded Access Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 55 North America CNS Conditions Interventional Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 56 North America CNS Conditions Observational Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 57 North America CNS Conditions Expanded Access Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 58 North America Diabetes Interventional Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 59 North America Diabetes Observational Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 60 North America Diabetes Expanded Access Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 61 North America Obesity Interventional Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 62 North America Obesity Observational Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 63 North America Obesity Expanded Access Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 64 North America Cardiovascular Diseases Interventional Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 65 North America Cardiovascular Diseases Observational Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 66 North America Cardiovascular Diseases Expanded Access Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 67 North America Others Interventional Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 68 North America Others Observational Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 69 North America Others Expanded Access Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 70 North America Protocol Designing Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 71 North America Site Identification Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 72 North America Patient Recruitment Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 73 North America Laboratory Services Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 74 North America Analytical Testing Services Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 75 North America Clinical Trial Data Management Services Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 76 North America Others Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 77 North America Pharmaceutical & Biopharmaceutical Companies Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 78 North America Medical Device Companies Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 79 North America Others Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 80 Country Outlook, 2024 & 2033
  • Fig. 81 US Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 82 Canada Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 83 Mexico Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)